, and also produced a further reduction in SeDBP vs the lower dose. All treatments were well tolerated, with similar low proportions of patients reporting treatmentemergent adverse events in all treatment groups. In conclusion, adding HCTZ to OM 40 mg significantly improves BP reductions and target BP rates in harderto-treat patients and a clear dose-response was observed for efficacy.
Introduction
Hypertension is closely associated with an increased risk of cardiovascular disease events. 1 In order to reduce the risk of cardiovascular disease associated with hypertension, health authorities have published guidelines that set maximum levels of acceptable blood pressure (BP), typically 140/90 or 130/80 mm Hg in patients with diabetes or at high cardiovascular risk, 2, 3 and have recently recommended that it may be prudent to consider lowering BP to values within the range 130-139/80-85 mm Hg in all hypertensive patients. 4 However, populationbased surveys show a high prevalence of hypertension in many countries, with 38% of men and 32% of women affected across both developed and developing countries. 5 Moreover, the frequency of uncontrolled BP in patients with hypertension who are receiving treatment is high. Estimates show that across all countries, only 11% of male and 17% of female patients receiving treatment for hypertension are controlled, and this underlines the need for improved patient management and more effective treatments. 5 The efficacy of antihypertensive therapy can be increased by combining agents from different classes, and studies have consistently shown that the majority of patients will require X2 antihypertensive agents in order to achieve target BP. 2, 3, 6 Treatment guidelines increasingly stress the role of combination therapy in the treatment of hypertension, especially for patients at increased CV risk 2, 3 and have highlighted the use of fixed dose combinations, on the basis that they improve compliance by simplifying therapy. 4 The European Society of Hypertension-European Society of Cardiology (ESH-ESC) guidelines recommend that agents used in combination therapy should have complementary mechanisms of action that provide greater efficacy than either monotherapy component together with a favourable tolerability profile. 3, 4 Several classes of antihypertensive agents are listed by the ESH-ESC guidelines as suitable for use in combination therapy, and these include thiazide diuretics and angiotensin II receptor blockers (ARBs). 3, 4 The ESH-ESC guidelines do not provide recommendations on the individual members of drug classes, but recently a meta-analysis of ambulatory BP studies involving ARBs has shown that the drug used and its dose level are determinants of BP reduction. 7 However, differences in angiotensin II (AT 1 ) receptor blockade observed with the various ARBs have been explained mainly by differences in dosing. 8 It can also be seen in the meta-analysis of Fabia et al. that the ARB olmesartan medoxomil (OM) provides effective BP reductions over 24-h, which are maintained during the night-time and last few hours of the dosing interval. 7 Pharmacodynamic studies support this notion 9, 10 and treating patients with the high (40 mg) dose of olmesartan should provide a high level of AT 1 -receptor blockade leading to increased BP reductions and control.
The addition of hydrochlorothiazide (HCTZ) 12.5 and 25 mg to OM 20 mg has been shown to deliver increased BP-lowering efficacy compared with continuation of OM 20 mg monotherapy in patients whose BP was inadequately controlled on OM 20 mg monotherapy. 11 However, the combination of HCTZ with the 40 mg dose of OM has not been evaluated in such a setting. Furthermore, relatively little data is available on the efficacy of OM 40 mg combined with HCTZ in patients with more severe hypertension. Such patients provide an important insight into efficacy as these patients often fail to achieve target BP, as illustrated by an analysis which found that in studies involving patients with high initial BP levels, the majority remained above or only slightly below SBP 140 mm Hg after treatment. 12 The present randomized study was designed to assess the antihypertensive efficacy and tolerability of HCTZ (12.5 and 25 mg) when used in combination with OM 40 mg in patients with grade 2 and grade 3 hypertension who had failed to achieve an adequate level of BP control following 8 weeks of treatment with open-label OM 40 mg. The study also assessed the efficacy of the combination of OM/HCTZ 40/12.5 mg compared with OM/HCTZ 20/12.5 mg.
Methods
This was a two-phase, randomized, double-blind, multi-national, parallel group Phase III study that was conducted at 78 sites in Europe (Bulgaria, Czech Republic, France, Germany, Poland, Spain, Ukraine). The study was designed and conducted in accordance with the ethical principles of the International Conference on Harmonisation guidelines for Good Clinical Practice and the Declaration of Helsinki. The study was approved by the relevant Independent Ethical Committee in each participating country, and each patient provided written informed consent before entering the study.
Patients
This study was conducted in men and women aged at least 18 years with grade 2 and grade 3 hypertension defined as a mean trough seated BP (SeBP) of X160/100 mm Hg at screening in newly diagnosed patients, or as a mean trough SeBP of X140/ 90 mm Hg in patients with a history of grade 2 and grade 3 hypertension who were receiving antihypertensive therapy before the study, including those treated with a stable dose of OM 20 Figure 1 ). Patients whose BP was controlled at the end of the open-label run-in period were discontinued.
All treatments were administered orally in the morning at approximately the same time. During the open-label treatment period, all patients took a single tablet of OM 40 mg once daily. During double-blind treatment, all patients took two tablets with the same appearance, which contained either an active study drug or a matching placebo. Concomitant administration of antihypertensive agents apart from the study medication or any other medication that may have affected the outcome was not permitted during the trial.
The primary efficacy variable was the mean change in trough SeDBP from the start of doubleblind treatment at week 8 (baseline) to the end of double-blind treatment at week 16. Secondary efficacy variables included the mean change from baseline to week 12 in mean SeDBP, and from baseline to weeks 12 and 16 in trough SeSBP; the number and proportion of patients who achieved target BP (SeBP o140/90 mm Hg in non-diabetic patients and SeBP o130/80 mm Hg in diabetic patients) at weeks 12 and 16. Secondary efficacy variables also included BP changes measured by ABPM.
Efficacy assessments
Recordings of vital measurements were made at screening, the start of the open-label treatment period (week 0), and at randomization, the mid point and end of the double-blind treatment period (weeks 8, 12 and 16, respectively), and at premature termination. All SeBP measurements were made at trough (24 ± 2 h after the last dose of study drug). At screening, BP measurements were made using each arm with the limb that gave the higher reading used for all subsequent measurements of BP. Each study centre used a standardised Greenlight 300 electronic sphygmomanometer (Accoson, Harlow, UK) to measure SeBP. For all SeBP measurements, patients were allowed to rest for X10 min before three recordings were made, at least 1 min apart.
Ambulatory BP measurements were carried out at weeks 0, 8 and 16 using a standard device (Spacelabs 90207, Spacelabs Healthcare, Issaquah, WA, USA). Ambulatory BP recordings were made every 15 min during the daytime (06:00 to o22:00) and every 30 min during the night-time (22:00 to o06:00).
Safety assessments
At screening, all patients provided a thorough medical history, including details of illnesses, surgery and allergies. A physical examination was performed at screening, and at the start and end of the double-blind treatment period, or at premature termination. A standard 12-lead electrocardiogram and laboratory tests for haematology, biochemistry and urinalysis were performed at screening, at the start of the open-label treatment period, at randomization and at the end of the double-blind treatment period, or at premature termination. Information about adverse events was gathered through examinations at study visits and by non-specific questioning of patients.
Statistical analysis
The study tested the hypotheses that in patients with grade 2 and grade 3 hypertension who had failed to achieve adequate BP control after 8 weeks of open-label treatment with OM 40 mg, the reduction in mean trough SeDBP would be superior with OM/HCTZ 40/25 mg or OM/HCTZ 40/12.5 mg The superiority of OM/HCTZ 40/25 mg over OM 40 mg was proved if the upper limit of the two-sided 95% confidence interval for the difference in least squares means for the SeDBP change from week 8 to week 16 from the parametric analysis of covariance with baseline SeDBP as covariate was less than zero. If a significant effect was observed then the superiority of OM/HCTZ 40/12.5 mg over OM 40 mg was tested in the same way and if this was found to be significant, then the superiority of OM/HCTZ 40/12.5 mg over OM 20/12.5 mg was similarly tested.
A sample size of 1050 patients (150 for the OM/ HCTZ 40/25 mg group and 300 each for the other groups) was chosen to provide 90% power with an alpha level of 5% to detect a difference of 3 and 2 mm Hg between the OM/HCTZ 40/25 mg and OM 40 mg groups, OM/HCTZ 40/12.5 mg and OM 40 mg groups, respectively, and to detect a difference of 2 mm Hg between the OM/HCTZ 40/12.5 and OM/ HCTZ 20/12.5 mg groups. This sample size assumed a standard deviation of 7.5 mm Hg for the change in SeDBP, and was sufficient to allow for withdrawals. A failure rate of 35% and a withdrawal rate of 30% were assumed for the screening and open-label treatment periods, respectively, which meant that 2300 patients needed to be screened and 1500 enrolled into the study.
The full analysis set comprised all patients who had received X1 dose of double-blind study medication and provided SeDBP data at baseline (week 8) and had made X1 visit during the doubleblind treatment period. The safety set comprised all randomized patients who received X1 dose of double-blind study medication. Analyses of the primary and secondary efficacy parameters were made on an intent-to-treat basis using the last observation carried forward principle. Analysis of the primary efficacy parameter was carried out using a parametric analysis of covariance model with treatment as a main effect and baseline mean trough SeDBP as a covariate.
Results

Patient disposition
A total of 2213 patients were screened, of whom 1226 entered the open-label treatment period (Figure 2) . During the open-label treatment period, 254 (20.7%) of patients withdrew prematurely, with the most frequent reasons for withdrawal being achievement of a satisfactory level of BP control (o140/90 mm Hg; 8.7% of patients), failure to satisfy seated or ambulatory BP criteria (7.7%), and withdrawal of consent (2.6%).
Of the patients who entered the open-label treatment period, 972 (79.3%) failed to achieve an adequate level of BP control, were randomized to double-blind treatment and comprised the full analysis set; the number who comprised the safety set was 971. In the double-blind treatment period, the numbers of patients randomized to OM/HCTZ 40/25 mg, OM/HCTZ 40/12.5 mg, OM/HCTZ 20/ 12.5 mg and OM/HCTZ 40/0 mg were 140, 278, 280 Changes in BP measured by ABPM over 24 h, the day-time and night-time also supported the primary and secondary efficacy results and further demonstrated that adding HCTZ to OM 40 mg significantly increases efficacy. Compared with OM 40 mg monotherapy, significant, dose-dependent reductions in ambulatory DBP and SBP were seen over 24 h, the daytime and night-time periods with OM 40 mg plus HCTZ ( Figure 5 ), although there were only slight differences between the 40/25 mg and 40/12.5 mg combinations. The largest reductions were seen in patients who received OM/HCTZ 40/25 mg, who showed reductions in ambulatory SBP over 24 h, the daytime and night-time periods that were 49 mm Hg greater than the changes seen in patients treated with OM 40 mg (Po0.0001 for each comparison). Reductions in ambulatory DBP over each of these observation periods were X5 mm Hg larger than those seen in patients treated with OM 40 mg (Po0.0001 for each comparison, Figure 5 ). The findings from analyses of patient subgroups also reflected the results of the primary and secondary efficacy parameters. Adding HCTZ 25 and 12.5 mg to OM 40 mg resulted in larger reductions in SeDBP and SeSBP and better levels of BP control in patients aged o65 years and in those aged X65 years, and in males and females. Moreover, these subgroup analyses showed no differences in BPlowering efficacy between patients aged o65 years compared with those aged X65 years, or between males and females (data not shown).
Tolerability and safety
All randomized treatments were well tolerated. The frequency of treatment-emergent adverse events was comparable across all four groups, was unaffected by combining OM with HCTZ (Table 2) , and the majority of these events were of mild intensity. There were 11 serious treatment-emergent adverse events in the open-label treatment period, and 12 in the double-blind treatment period, all of which were considered to be unrelated or unlikely to be related to treatment. Overall, the percentage of patients who withdrew because of a treatment-emergent adverse event was low, below 2.2 and 2% in each group during the open-label and double-blind treatment periods, respectively, and showed no relation to study treatment. The most commonly reported adverse events during double-blind treatment were metabolic and nutrition disorders that ranged from 0.4% in the OM/HCTZ 40/12.5 mg group to 5.0% in the OM/HCTZ 40/25 mg group, headache that ranged from 0.7% in the OM/HCTZ 40/12.5 mg group to 2.9% in the OM 40 mg monotherapy group, and hyperuricaemia that ranged from 0.0% in the OM/HCTZ 40/12.5 mg and OM 40 mg monotherapy groups to 2.1% in the OM/HCTZ 40/25 mg group. In regard to adverse events of special interest, the overall frequency of hypotension and dizziness/ vertigo was low (o1% of patients per group), headache affected o3% of patients in each group, and these events were considered to be unrelated to treatment. Mean blood glucose concentrations showed clinically relevant increases in o1% of patients in each group, and clinically relevant increases in uric acid, creatinine and potassium concentrations were also seen infrequently and showed no correlation with the treatment given. No cases of hypokalaemia or hyperkalaemia were reported during double-blind treatment. Two cases of syncope were reported during double-blind treatment (both in the OM/HCTZ 40/12.5 mg group), each of which was judged to be unrelated to treatment. The percentage of patients in whom laboratory tests revealed anomalies was low: elevated alanine-aminotransferase levels were reported in one patient each in the OM/HCTZ 40/25 and 40/12.5 mg groups, elevated aspartate-aminotransferase levels in one patient each in the OM/HCTZ 40/25 and OM 40 mg monotherapy groups, and elevated g-GT levels in two patients in the OM/HCTZ 40/12.5 mg group.
Discussion
This was a large randomized study with the primary aim of evaluating the additional antihypertensive effect on SeDBP of adding HCTZ 12. 5 mg or 25 mg to OM 40 mg in patients with grade 2 and grade 3 hypertension who had failed to achieve a satisfactory level of BP control after 8 weeks of treatment with OM 40 mg monotherapy. Compared with patients who were randomized to continue on OM 40 mg monotherapy, the addition of HCTZ to OM 40 mg produced stepwise dose-dependent reductions in SeDBP with a similar tolerability profile. The changes in SeSBP were consistent with those seen in the primary efficacy parameter, and significant, clinically relevant reductions in SeSBP and SeDBP were seen with each combination of OM 40 mg plus HCTZ, with the greatest reductions seen with the OM/HCTZ 40/25 mg combination. The study also found that the OM/HCTZ 40/12.5 mg combination produced a significantly larger reduction in SeSBP than the OM/HCTZ 20/12.5 mg combination, and a reduction in SeDBP that was numerically but not significantly larger. Overall, the range of treatments used in the study showed a clear dose response for changes in DBP and SBP.
A dose response was also obvious in the numbers of patients who achieved target BP across the different groups, as shown by the significantly increased odds of achieving target BP with OM 40 mg combined with HCTZ compared with OM 40 mg monotherapy. At week 16, more than 40% of patients treated with OM/HCTZ 40/25 mg and nearly 40% of those treated with OM/HCTZ 40/12.5 mg had achieved target BP, compared with less than 25% of patients treated with OM 40 mg monotherapy. In patients treated with OM/HCTZ 20/12.5 mg, target BP achievement was greater than 30%. Thus, BP target achievement was substantially improved by adding HCTZ to OM 40 mg, with the response dependent upon the dose combination used and greatest with the OM/HCTZ 40/25 mg combination.
The efficacy of ARBs depends upon their ability to produce a sustained blockade of vascular AT 1 receptors. Various factors, including dose level, receptor binding and pharmacokinetic parameters, affect the capacity of ARBs to block the AT 1 receptor and ARBs have been shown to differ in these areas. 8, 10, 13 This is demonstrated by a recent study of the effects of several ARBs on the pressor response to exogenously administered angiotensin II. The increase in BP produced by angiotensin II administration was almost completely blocked by both OM 20 mg and irbesartan 300 mg, but only partially blocked by valsartan 160 mg and losartan 100 mg. 13 Importantly, the addition of HCTZ to either OM 20 mg or irbesartan 300 mg had no significant effect on their ability to antagonize the activity of the AT 1 receptor. 13 Such findings are inline with in vitro studies, which show that OM produces a strong blockade of the AT 1 receptor, with a high degree of insurmountable binding, slow dissociation and high affinity for the AT 1 receptor. 14 The clinical consequences of this robust inhibition of the AT 1 receptor appear as the sustained reductions in SBP and DBP over 24 h seen in the metaanalysis of Fabia et al. 7 Direct clinical comparisons in which OM produced larger reductions in BP measured by ABPM than several other ARBs may also reflect stronger AT 1 receptor blockade [15] [16] [17] The 2009 re-appraisal of the ESH-ESC guidelines on hypertension management acknowledge that, in general, in up to 20% of patients with hypertension BP control cannot be achieved by a two-drug combination. 4 However, even treatment with an ARB with superior AT 1 receptor binding characteristics may not lead to high rates of BP goal achievement in a population that includes a high proportion of patients with severe hypertension. Such patients may be candidates for triple therapy with an ARB/calcium channel blocker/HCTZ combination.
Ambulatory BP monitoring, was also used to assess changes in BP in this study and showed that adding HCTZ produced significant and clinically meaningful reductions in DBP and SBP that were additional to the effect of OM 40 mg monotherapy. For the OM/HCTZ 40/25 mg group, the mean reductions in ambulatory SBP over 24 h, the daytime and night-time were all more than 9 mm Hg larger than the reductions produced by OM 40 mg monotherapy. These findings are further evidence of the efficacy of OM 40 mg plus HCTZ as ABPM provides a more robust and informative insight into
What is known about topic K European treatment guidelines recommend that thiazide diuretics and ARBs can be used in combination therapy in patients with hypertension. K Combining ARBs with HCTZ produces greater increases in efficacy compared with increasing the dose of either component monotherapy, and adding HCTZ to OM 20 mg has been shown to significantly reduce BP compared with OM 20 mg monotherapy.
What this study adds K In harder-to-treat patients with grade 2 and grade 3 hypertension, adding HCTZ to the high (40 mg) dose of OM produced clinically meaningful, significant improvements in SeSBP, SeDBP and in target BP achievement compared with high-dose OM monotherapy without any increase in undesirable effects including elevations in blood glucose or reductions in potassium levels.
